Anti-tumor effect by inhibition of NF-κB activation using nafamostat mesilate for pancreatic cancer in a mouse model

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 843-850

  Furukawa, Kenei ^a   Iida, Tomonori ^a   Shiba, Hiroaki ^a   Fujiwara, Yuki ^a   Uwagawa, Tadashi ^a   Shimada, Yohta ^a   Misawa, Takeyuki ^a   Ohashi, Toya ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Nafamostat mesilate; NF B inhibitor; Pancreatic cancer

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAFAMSTAT MESILATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GUANIDINES; HUMANS; MALE; MICE; MICE, NUDE; NF-KAPPA B; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957361331     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000928     Document Type: Article

References (41)

1. Niederhuber JE, Brennan MF and Menck HR: The National Cancer Date Base report on pancreatic cancer. Cancer 76: 1671-1677, 1995.
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002. (Pubitemid 34831525)
4. Chen F, Castranova V and Shi X: New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol 159: 387-397, 2001. (Pubitemid 32751067)
5. Amer BA and David B: An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science 274: 782-784, 1996.
6. Antwerp VDJ, Seamus MJ, Tal K, Douglas GR and Inder VM: Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
7. Karin M and Lin A: NF-κB at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
8. Huang S, Robinson JB, DeGuzman A, Bucana CD and Fiddler IJ: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-5339, 2000.
9. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M and Umezawa K: Targeting of nuclear factor κB pathways by Dehydroxymethyleoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11: 1287-1293, 2005. (Pubitemid 40175782)
10. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K and Kurai M: Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 63: 107-110, 2003. (Pubitemid 36070427)
11. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001. (Pubitemid 32762193)
12. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiano PJ: The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999. (Pubitemid 29045184)
13. Wang W, Abbruzzese JL, Evans DB and Chiano PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regurated by constitutively activated RelA. Oncogene 18: 4554-4563, 1999. (Pubitemid 29405887)
14. Fujioka S, Sclabas GM, Schmidit C, Niu J, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. Oncogene 22: 1365-1370, 2003. (Pubitemid 36384598)
15. Fujioka S, Sclabas GM, Schmidit C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiano PJ: Function of nuclear κB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-354, 2003.
16. Uwagawa T, Li Z, Chang Zhe, Xia Q, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, Abbruzzese JL and Chiano PJ: Mechanisms of synthetic serine protease inhibitor (FUT-175)- mediated cell death. Cancer 109: 2142-2153, 2007.
17. Uwagawa T, Chiano PJ, Gocyo T, Hirohara S, Misawa T and Yanaga K: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-κB activation. Anticancer Res 29: 3173-3178, 2009.
18. Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, Wakiyama S, Hirohara S, Sadaoka S and Yanaga K: A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol 20: 239-243, 2009.
19. Fujii S and Hitomi Y: New synthetic inhibitors of C1r, C1 esterase, thrombin, kallikrein and trypsin. Biochim Biophys Acta 661: 342-345, 1981.
20. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S and Fujita M: Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35: 207-227, 1984.
21. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M and Aoyama T: Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Phamacol 41: 155-162, 1986.
22. Takahashi H, Takizawa S, Tatewaki W, Nagai K, Wada K, Hanano M and Shibata A: Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulations. Thromb Haemost 62: 372, 1989.
23. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K and Kitamura N: Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 93: 215-217, 1991.
24. + transport properties in the rabbit cortical collecting duct. Br J Pharmacol 109: 673-678, 1993.
25. + transport properties in the rabbit cortical collecting duct. Br J Pharmacol 111: 173-178, 1994.
26. Kitagawa H, Chang H and Fujita T: Hyperkalemia due to nafamostat mesylate. N Engl J Med 332: 687, 1995.
27. Shimada Y, Fukuda T, Aoki K, Yukawa T, Iwamuro S, Ohkawa K and Takada K: A protocol for immunoaffinity separation of the accumulated ubiquitin-protein conjugates solubilized with sodium dodecyl sulfate. Anal Biochem 377: 77-82, 2008.
28. Tsuzuki H, Tani T and Hanazawa K: Regulation of NF-κB. Iyakunomonn 43: 162-167, 2003 (in Japanese).
29. Chen CL, Wang SD, Zeng ZY BSc, Lin KJ, Kao ST, Tani T, Yu CK and Wang JY: Serine protease inhibitors nafamostat mesilate and gabexate mesilate atteneuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 118: 105-112, 2006.
30. Kimura T, Fuchimoto S, Iwagaki H, Hizuta A and Orita K: Inhibitory effect of nafamoatat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. J Int Med Res 20: 343-352, 1992.
31. Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G and Miwa K: Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol 23: 61-66, 2003.
32. Tajima H, Ohta T, Elnemr A, Yasui T, Kitagawa H, Fushida S, Kayahara M, Miwa K, Wakayama T, Iseki S and Yokohama S: Enhanced invasion of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA. Int J Cancer 94: 699-704, 2001.
33. Uchima Y, Sawada T, Nishihara T, Maeda K, Ohira M and Hirakawa K: Inhibition and mechanism of a protease inhibitor in human pancreatic cancer cells. Pancreas 29: 123-131, 2004.
34. Yoon WH, Jung YJ, Kim TD, Li G, Park BJ, Kim JY, Lee YC, Kim JM, Park JI, Park HD, No ZS, Lim K, Hwang SD and Kim YS: Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix matalloproteinases and angiogenesis. Clin Cancer Res 10: 4517-4526, 2004.
35. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
36. Singh S and Aggarwal BB: Activation of transcription NF-κB is suppressed by curcumin (diferuloylmethan). J Biol Chem 270: 24995-25000, 1995.
37. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
38. Moos PJ, Edes K, Mullally JE and Fitzpatrick FA: Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 25: 1611-1617, 2004.
39. Holmes-McNary M and Baldwin AS Jr: Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB. Cancer Res 60: 3477-3483, 2000.
40. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S and Aggarwal BB: Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127: 257-268, 2009.
41. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR and Kim AL: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283, 2007.